The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III trial of neoadjuvant chemotherapy (NAC) with methotrexate, doxorubicin, vinblastine, and cisplatin (MVAC) followed by radical cystectomy (RC) compared with RC alone for muscle-invasive bladder cancer (MIBC): Japan Clinical Oncology Group study, JCOG0209.
Hiroshi Kitamura
No relevant relationships to disclose
Taiji Tsukamoto
No relevant relationships to disclose
Naoya Masumori
No relevant relationships to disclose
Taro Shibata
No relevant relationships to disclose
Futoshi Kunieda
No relevant relationships to disclose
Hiroyuki Fujimoto
No relevant relationships to disclose
Yoshihiko Hirao
No relevant relationships to disclose
Yasuo Kitamura
No relevant relationships to disclose
Yoshihiko Tomita
No relevant relationships to disclose
Kenichi Tobisu
No relevant relationships to disclose
Masashi Niwakawa
No relevant relationships to disclose
Seiji Naito
No relevant relationships to disclose
Masatoshi Eto
No relevant relationships to disclose
Yoshiyuki Kakehi
No relevant relationships to disclose